Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia.

@article{VelaNavarrete2005SerenoaRT,
  title={Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia.},
  author={Remigio Vela-Navarrete and Marta Escribano-Burgos and Antonio J. L{\'o}pez Farr{\'e} and Juan V Garcia-Cardoso and F{\'e}lix Manzarbeitia and Carolina D. Carrasco},
  journal={The Journal of urology},
  year={2005},
  volume={173 2},
  pages={507-10}
}
PURPOSE Permixon is a lipidosterolic extract of Serenoa repens (SR) widely used to treat men with benign prostatic hyperplasia (BPH). We tested the effect of this drug on molecular mechanisms associated with apoptosis, such as the Bax-to-Bcl-2 expression ratio and caspase-3 activity, in prostatic tissue from men with symptomatic BPH treated for 3 months before surgery. MATERIALS AND METHODS An open, multicenter pilot study of 2 parallel groups of patients with BPH was done. They were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…